- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC
September 8th 2025, 9:26pm
IASLC World Conference on Lung Cancer
Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.
Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology
September 8th 2025, 9:13pm
IASLC World Conference on Lung Cancer
Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.
Tepotinib Generates Superior Responses in Adenocarcinoma vs Non-Adenocarcinoma MET Exon 14 Skipping NSCLC
September 8th 2025, 9:04pm
IASLC World Conference on Lung Cancer
Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.
Final Analysis of Perioperative Tislelizumab Plus Chemotherapy Shows Sustained OS and EFS Improvement in Resectable NSCLC
September 8th 2025, 8:37pm
IASLC World Conference on Lung Cancer
Perioperative tislelizumab plus chemotherapy showed sustained OS and EFS improvement vs chemotherapy in resectable NSCLC.
ABBV-706 Yields Durable Responses and Is Deemed Tolerable in R/R SCLC
September 8th 2025, 7:12pm
IASLC World Conference on Lung Cancer
The SEZ6-targeting ADC ABBV-706 generated durable efficacy outcomes comparable with those of first-line SOC in patients with relapsed/refractory SCLC.
Signatera Genome Assay Demonstrates Strong Prognostic Value in Early-Stage Resectable NSCLC
September 8th 2025, 7:05pm
IASLC World Conference on Lung Cancer
A correlation between ctDNA negativity in the post-surgical MRD window and improved RFS and OS was observed with the Signatera Genome assay in NSCLC.
Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases
September 8th 2025, 6:24pm
IASLC World Conference on Lung Cancer
Dato-DXd demonstrated CNS PFS and ORR benefits vs docetaxel in patients with NSCLC with brain metastases.
Concurrent Durvalumab and Chemoradiotherapy Fails to Provide Survival Advantage in Unresectable, Stage III NSCLC
September 8th 2025, 6:00pm
IASLC World Conference on Lung Cancer
Durvalumab/chemoradiation followed by consolidation durvalumab did not improve OS vs chemoradiation followed by durvalumab in stage III NSCLC.
Exploring the Latest in EGFR-Mutant Lung Cancer With Drs Ramalingam and Raez
September 8th 2025, 4:55pm
OncLive News Network: On Location at WCLC 2025
Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Taletrectinib Demonstrates Durable Responses in TKI-Naive and -Pretreated ROS1+ NSCLC
September 8th 2025, 4:50pm
IASLC World Conference on Lung Cancer
Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.
Perioperative Pembrolizumab Plus Chemo Yields Improved Survival, Responses in Early-Stage Resectable NSCLC
September 8th 2025, 4:10pm
IASLC World Conference on Lung Cancer
Perioperative pembrolizumab demonstrated improved mPR, pCR, EFS, and OS in patients with early-stage resectable NSCLC and any nodal status.
Adjuvant Nivolumab Plus Chemo Decreases Disease Relapse Rates vs Chemo in Resected NSCLC
September 8th 2025, 4:02pm
IASLC World Conference on Lung Cancer
Adjuvant nivolumab plus chemotherapy led to a clinically meaningful reduction in relapse rates vs chemotherapy in resected NSCLC.
Ifinatamab Deruxtecan Elicits Responses in Previously Treated Extensive-Stage Small Cell Lung Cancer
September 7th 2025, 9:51pm
IASLC World Conference on Lung Cancer
Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.
Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC
September 7th 2025, 7:42pm
IASLC World Conference on Lung Cancer
The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.
Ivonescimab Plus Chemo After Third-Generation TKI Generates Improved PFS in EGFR-Mutated NSCLC
September 7th 2025, 6:11pm
IASLC World Conference on Lung Cancer
Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.
Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC
September 7th 2025, 5:55pm
IASLC World Conference on Lung Cancer
Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.
Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC
September 7th 2025, 5:49pm
IASLC World Conference on Lung Cancer
Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.
Adjuvant Crizotinib Fails to Produce DFS, OS Benefit Over Observation in Resected ALK+ NSCLC
September 7th 2025, 5:23pm
IASLC World Conference on Lung Cancer
Results from the ALCHEMIST trial show that adjuvant crizotinib did not improve DFS or OS vs observation in resected ALK-positive NSCLC.
Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC
September 7th 2025, 2:54pm
IASLC World Conference on Lung Cancer
Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.
Aumolertinib Plus Chemotherapy Improves PFS in EGFR-Mutated NSCLC
September 7th 2025, 2:07pm
IASLC World Conference on Lung Cancer
The addition of aumolertinib to chemotherapy improved PFS vs aumolertinib monotherapy for the treatment of patients with EGFR-mutated NSCLC.